Author:
Merseburger Axel S.,Chowdhury Simon,Bahl Amit
Reference10 articles.
1. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer;Smith;N Engl J Med,2022
2. Saad F, Hussain M, Tombal B, et al. Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: analyses of the randomized phase 3 ARASENS study. Eur Urol. In press.
3. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer;Chowdhury;Ann Oncol,2023
4. LBA-10 ARCHES – efficacy of androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: prostate-specific antigen results;Stenzl;J Urol,2019
5. 1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide plus androgen deprivation therapy (ADT);Merseburger;Ann Oncol,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献